Skip to content
2000
Volume 21, Issue 5
  • ISSN: 1570-1646
  • E-ISSN: 1875-6247
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

Background

Multiple Myeloma (MM) is a hematologic malignancy that often progresses to a refractory relapse, posing significant treatment challenges due to prior treatments, drug response duration, clinical and molecular characteristics, comorbidities, and adverse reactions.

Methods

This single-center and single-arm study assessed the BPD regimen, which includes bendamustine, pomalidomide, and dexamethasone, for its efficacy and safety in 21 patients with Relapsed and Refractory Multiple Myeloma (RRMM), including those who were intolerant to prior bortezomib treatment.

Results

The Overall Response Rate (ORR) after 1-8 cycles of BPD treatment was 58.8%. The 6- month Progression-Free Survival (PFS) was 70.5%, and the 12-month PFS was 52.9%. The 1-year Overall Survival (OS) rate was 82.35%. Hematologic toxicities were the main adverse reactions, with grade 3 or higher adverse events mainly linked to hematologic toxicity and infections.

Conclusion

The BPD regimen has shown to be highly effective, with a favorable ORR and survival rate in RRMM patients, indicating it a relatively safe and well-tolerated treatment option.

© 2024 The Author(s). Published by Bentham Science Publishers.
 This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/cp/10.2174/0115701646317932240830073816
2024-09-12
2025-10-31

  • From This Site

    /content/journals/cp/10.2174/0115701646317932240830073816
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cp/21/5/CP-21-5-06.html?itemId=/content/journals/cp/10.2174/0115701646317932240830073816&mimeType=html&fmt=ahah

References

  1. MukkamallaS.K.R. MalipeddiD. Myeloma Bone Disease: A Comprehensive Review.Int. J. Mol. Sci.20212212620810.3390/ijms2212620834201396
     [Google Scholar]
  2. RamasamyK. IqbalG. BrouwerR. StalkerV. AkhtarS. VargheseS. LindsayJ. ScheyS. DraysonM. DunnJ. Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial.Blood Cancer J.2022121116210.1038/s41408‑022‑00758‑736446771
     [Google Scholar]
  3. LaroccaA. MinaR. GayF. BringhenS. BoccadoroM. Emerging drugs and combinations to treat multiple myeloma.Oncotarget2017836606566067210.18632/oncotarget.1926928948001
     [Google Scholar]
  4. Açarİ.H. GüvençB. Efficacy of Bendamustine, Pomalidomide, and Dexamethasone (BPD) regimen in relapsed/refractory extramedullary myeloma: A retrospective single-centre study, real-life experience.Hematol. Rep.202315346547310.3390/hematolrep1503004837606493
     [Google Scholar]
  5. GayF. GüntherA. OffidaniM. EngelhardtM. SalviniM. MontefuscoV. PatriarcaF. AquinoS. PönischW. SpadaS. SchubN. GentiliS. WäschR. CorradiniP. StrakaC. PalumboA. EinseleH. BoccadoroM. SonneveldP. GramatzkiM. Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network.Cancer2021127183413342110.1002/cncr.3364734181755
     [Google Scholar]
  6. HeJ. HeD. HanX. ZhengG. WeiG. ZhaoY. YangY. WuW. FuJ. ShouL. KongH. HuangH. CaiZ. Bortezomib-based regimens for newly diagnosed multiple myeloma in China: A report of 12-year real-world data.Front. Pharmacol.20201156160110.3389/fphar.2020.56160133362538
     [Google Scholar]
  7. RajkumarS.V. HarousseauJ.L. Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.Blood2016128242757276410.1182/blood‑2016‑09‑69294727742709
     [Google Scholar]
  8. TessenowH. HolzvogtM. HolzvogtB. AndreaM. HeynS. SchliwaT. SchwarzM. ZehrfeldT. BeckerC. PfrepperC. FrankeG.N. KrahlR. JentzschM. LeibleinS. SchwindS. BillM. VucinicV. LangeT. NiederwieserD. PönischW. Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).J. Cancer Res. Clin. Oncol.2017143102049205810.1007/s00432‑017‑2439‑x28534173
     [Google Scholar]
  9. LengS. BhutaniD. RazaS. AssalA. PanS. HuJ. WeiA. MaparaM. LentzschS. Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma.Blood Cancer J.20201021310.1038/s41408‑020‑0278‑532015343
     [Google Scholar]
  10. Fevzi FıratY. NihanA. AyşeS. CemM. Clinical outcomes related to the use of bendamustine therapy for multiple myeloma patients relapsed/refractory to immunomodulatory drugs and proteasome inhibitors.Turk. J. Haematol.2017343
     [Google Scholar]
  11. GentileM. RecchiaA.G. MazzoneC. VignaE. MartinoM. MorabitoL. LuciaE. BossioS. De StefanoL. GranataT. PalummoA. MorabitoF. An old drug with a new future: bendamustine in multiple myeloma.Expert Opin. Pharmacother.201314162263228010.1517/14656566.2013.83788524053161
     [Google Scholar]
  12. ScheyS. BrownS.R. TillotsonA.L. YongK. WilliamsC. DaviesF. MorganG. CavenaghJ. CookG. CookM. OrtiG. MorrisC. SherrattD. FlanaganL. GregoryW. CavetJ. MyelomaU.K.E.P.C.T.N. Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUK one randomized dose selection trial.Br. J. Haematol.2015170333634810.1111/bjh.1343525891006
     [Google Scholar]
  13. GrzaskoN. CharlinskiG. MorawskaM. KicinskiP. Waszczuk-GajdaA. Drozd-SokolowskaJ. SuboczE. BlonskaD. RaznyM. Druzd-SitekA. HolojdaJ. SwiderskaA. Usnarska-ZubkiewiczL. MasternakA. GiannopoulosK. Bendamustine-based regimens as salvage therapy in refractory/relapsed multiple myeloma patients: A retrospective real-life analysis by the polish myeloma group.J. Clin. Med.20211023550410.3390/jcm1023550434884206
     [Google Scholar]
  14. WangJ. YaoY. ShangJ.J. MaX. FuC.C. WuD.P. JinS. [Efficacy and safety of bendamustine combined with pomalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma].Zhonghua Xue Ye Xue Za Zhi202344650450737550209
     [Google Scholar]
  15. CerchioneC. NappiD. Di PernaM. ZacheoI. MigliaccioI. SalvatoreD. PicardiM. PaneF. CatalanoL. A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide.Clin. Case Rep.20175450550710.1002/ccr3.77328396778
     [Google Scholar]
  16. KumarS. SharmaA. MalikP.S. GogiaA. PathakN. SahooR.K. GuptaR. PrasadC.P. KumarL. Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial.Br. J. Haematol.2022198228829710.1111/bjh.1820035499209
     [Google Scholar]
  17. PönischW. MollB. BourgeoisM. AndreaM. SchliwaT. HeynS. SchmalfeldM. EdelmannT. BeckerC. HoffmannF.A. SchwarzerA. KreibichU. EgertM. StieglerR. KrahlR. RemaneY. BachmannA. LindnerT. WeidhaseL. PetrosS. FrickeS. VucinicV. Al AliH. NiederwieserD. Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure.J. Cancer Res. Clin. Oncol.2013139111937194610.1007/s00432‑013‑1513‑224046251
     [Google Scholar]
  18. PönischW. HeynS. BeckJ. WagnerI. MohrenM. HoffmannF.A. LangeT. SchmalfeldM. ZehrfeldT. SchwarzerA. WinkelmannC. EdelmannT. RöhrbornR. HebenstreitK. Al-AliH.K. JäkelN. NiederwieserD. Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO – #077.Br. J. Haematol.2013162220220910.1111/bjh.1236123692564
     [Google Scholar]
  19. CerchioneC. CatalanoL. PelusoI. NappiD. Di PernaM. SalvatoreD. MigliaccioI. PicardiM. PaneF. Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone.Support. Care Cancer201624124835483710.1007/s00520‑016‑3430‑927726031
     [Google Scholar]
  20. IssaI.I. BrøndumR.F. DueH. SchmidtL. BøgstedM. DybkærK. A bendamustine resistance gene signature in diffuse large B-cell lymphoma and multiple myeloma.Cancer Drug Resist.20214120822235582014
     [Google Scholar]
  21. LeeH.C. FengL. OriabureO. GrahamV. ChenW. BadilloM. LuR. LeeH.J. JainP. ManasanchE.E. OrlowskiR.Z. WangM.L. A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma.Am. J. Hematol.2021967E243E24610.1002/ajh.2617833811767
     [Google Scholar]
  22. DhakalB. D’SouzaA. HamadaniM. Arce-LaraC. SchroederK. ChhabraS. ShahN.N. GaugerK. KeatonT. PasquiniM. HariP. Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma.Blood Cancer J.2019985610.1038/s41408‑019‑0219‑331358733
     [Google Scholar]
  23. SivarajD. GreenM.M. KangY. LongG.D. RizzieriD.A. LiZ. GarrettA.H. McIntyreJ.L. ChaoN.J. GasparettoC. Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma.Blood Cancer J.2018887110.1038/s41408‑018‑0104‑530065277
     [Google Scholar]
  24. MustoP. FraticelliV.L. MansuetoG. MadonnaE. NozzaA. AndrianiA. MussettiA. BallantiS. BongarzoniV. BaraldiA. PatriarcaF. VincelliD. FalconeA. DerudasD. CalifanoC. ZambelloR. MeleG. FragassoA. BaldiniL. StortiS. Bendamustine in relapsed/refractory multiple myeloma: the “real-life” side of the moon.Leuk. Lymphoma20155651510151310.3109/10428194.2014.98264425651428
     [Google Scholar]
  25. FaragS. BacherU. JekerB. LegrosM. RhynerG. LüthiJ.M. SchardtJ. ZanderT. DaskalakisM. MansouriB. ManzC. PabstT. Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial.Bone Marrow Transplant.202257699099710.1038/s41409‑022‑01681‑y35444232
     [Google Scholar]
/content/journals/cp/10.2174/0115701646317932240830073816
Loading
The Efficacy and Safety Analysis of the Bendamustine, Pomalidomide, and Dexamethasone (BPD) Combination Treatment for Patients with Proteasome Inhibitor Intolerance and/or Relapsed Multiple Myeloma
Curr. Proteomics 21, 341 (2024); https://doi.org/10.2174/0115701646317932240830073816
/content/journals/cp/10.2174/0115701646317932240830073816
/content/journals/cp/10.2174/0115701646317932240830073816
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): bendamustine; dexamethasone; Multiple myeloma; pomalidomide; proteasome inhibitor intolerance; relapse

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test